MDxHealth SA Dossier - Source-backed chat

MDxHealth SA

MDXHNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-334,428.80

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.58Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $55M

Enterprise Value $102.1M

Shares Outstanding 95.4M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MDxHealth is transitioning into a highly focused, pure-play urology precision diagnostics leader following its strategic decision to discontinue the volatile Resolve UTI testing business. By closing its Plano, Texas laboratory and focusing entirely on its core prostate cancer menu (Confirm mdx, GPS mdx, ExoDx, and Select mdx), the company is eliminating reimbursement volatility and resetting its growth trajectory. Despite near-term headwinds from a $10.4 million Medicare recoupment demand, the core prostate cancer business remains robust, growing at 11% pro forma in Q1 2026 and guided to grow 20-26% for the full year 2026. The integration of ExoDx and GPS provides an unmatched clinical pathway for urologists, positioning the company for sustainable long-term growth and operating leverage.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$2.20

High · most bullish analyst$4.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.50

The Medicare recoupment demand of $10.4 million is upheld in full, forcing immediate cash outflows that severely strain the balance sheet. Restructuring and exit costs for the Plano lab closure exceed expectations, and tissue-based test volumes continue to decline due to competitive pressures or clinical mix shifts. The company fails to reach its core revenue guidance and is forced to raise highly dilutive equity capital to meet its deferred earnout obligations to Exact Sciences.

Base CaseCentral scenario

$4.00

MDxHealth successfully executes its focus on the core prostate cancer diagnostics menu, delivering FY2026 core revenue of $110-$115 million (20-26% YoY growth). The wind-down of the Resolve UTI business is completed in orderly fashion, removing reimbursement volatility from the financial profile. The company continues to contest the $10.4 million Novitas recoupment demand through formal appeals, limiting immediate cash outflows. Operating discipline leads to progress toward a 10% adjusted EBITDA margin run rate exiting 2026, supported by a solid pro forma cash position.

Bull CaseUpside scenario

$5.00

The core prostate cancer business accelerates faster than expected, driven by deep market penetration of the integrated sales force and rapid adoption of the ExoDx liquid biopsy test. Restructuring charges from the Resolve UTI wind-down are minimal, and the company successfully appeals or significantly reduces the $10.4 million Medicare recoupment demand. Operating leverage drives the adjusted EBITDA margin run rate well past the 10% target exiting 2026, leading to early profitability and a re-rating of the stock toward historical multiples.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Comprehensive, clinically validated prostate cancer diagnostic menu covering the entire clinical pathway.
Strategic exit from the volatile UTI testing market, eliminating reimbursement uncertainty and streamlining operations.
Strong core organic growth (guided at 20-26% for FY2026) with established reimbursement and NCCN/AUA guideline inclusion.
Significant operating leverage potential following the integration of the ExoDx and GPS acquisitions.

Key Investment Risks

Outstanding Medicare recoupment demand of up to $10.4 million from Novitas.
Near-term restructuring and exit costs associated with closing the Plano, Texas laboratory facility.
Tight cash flow and substantial deferred earnout obligations to Exact Sciences ($15M paid in April 2026, with $18M and $21.5M due in 2027 and 2028 respectively).
Dependence on commercial payor and Medicare reimbursement policies for molecular diagnostics.

Thesis Invalidation Triggers

Unfavorable final rulings on the Medicare recoupment appeals leading to immediate cash drain.
Core prostate cancer revenue growth falling below the guided 20% floor for FY2026.
Inability to improve adjusted EBITDA margins due to persistent operational inefficiencies or rising commercialization costs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.